ESG Reports — Imugene (ASX: IMU)

About

Mission and Values

Leadership Team

Management Team

Scientific Advisory Board

Corporate Governance

Technology

Allogeneic CAR T Cell Therapy

OnCARlytics (CF33-CD19)

Oncolytic Virus (CF33)

B-Cell Immunotherapies

Pipeline

Clinical Pipeline

Clinical Trials

Investors

ASX Announcements

Investor Presentations

Conference Presentations

Analyst Coverage

Half Yearly Report

Quarterly Report

Live Share Price

About

Mission and Values

Leadership Team

Management Team

Scientific Advisory Board

Corporate Governance

Technology

Allogeneic CAR T Cell Therapy

OnCARlytics (CF33-CD19)

Oncolytic Virus (CF33)

B-Cell Immunotherapies

Pipeline

Clinical Pipeline

Clinical Trials

Investors

ASX Announcements

Investor Presentations

Conference Presentations

Analyst Coverage

Half Yearly Report

Quarterly Report

Live Share Price

Screen Shot 2022-08-31 at 2.46.54 pm.png

ESG Reports

Investors
ASX Announcements
Investor Presentations
Conference Presentations
Analyst Coverage
Annual Reports
Half Yearly Report
Quarterly Report
Live Share Price
Media
Videos
Newsletters
ESG Reports

Imugene ESG Report 2024

Imugene ESG Report 2023

Imugene ESG Report 2022

Imugene Limited, Suite 12.01, Level 12, 4-6 Bligh Street, Sydney, NSW, 2000, Australia

Imugene Limited ABN 99 009 179 551 Australia

Imugene acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Site by BDAC